Analyst consensus rating
ARS Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
ARS Pharmaceuticals's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked November 16, 2026.
Get free ARS Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.89
- Average price target
- $17.00
- High price target
- $20.00
- Low price target
- $14.00
- Low target gap
- +259.9%
- Target upside
- +337%
- High target gap
- +414.1%
- Target range width
- 154.2%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- November 16, 2026
- Valid through
- November 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ARS Pharmaceuticals?
ARS Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $17.00.
How far are ARS Pharmaceuticals's low and high targets from the recorded price?
The low target implies +259.9%, while the high target implies +414.1%.
How many analysts are included in ARS Pharmaceuticals's consensus?
The verified consensus includes 3 analysts.
How is ARS Pharmaceuticals's target upside or downside calculated?
The average target of $17.00 is divided by the recorded price of $3.89, then one is subtracted to produce +337%. This does not guarantee a future return.
When was ARS Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.